Up Regulation of Ezrin and Radixin with respect to Grade of Tumors in Breast Cancer Patients
Abstract
Background: Breast cancer (BC) is one of the main causes of death among women in Iran. Biomarkers involved in promotion and progression of disease is very important in management and control of BC outcomes. In this research, we aim to estimate the expression levels of Ezrin and Radixin, as two important factors in morphogenesis, endocytosis, exocytosis, adherence, and migration of cells, in BC patients and their relationship with pathological factors. Methods: One hundred and thirteen BC patients were involved in this research. Relative expression of Ezrin and Radixin genes were estimated with quantitative real-time PCR. Pathological data include the histology, tumor size, grade, lymphovascular invasion and clinical TNM (Tumor, Node, and Metastasis) staging of patients were recorded based on the pathology report and their relationship with relative expression of Ezrin and Radixin were estimated. Result: According to result Ezrin were over expressed in tumor samples in comparison to adjacent normal tissue. There is a significant relationship between over expression of Ezrin and Radixin and grade of tumor and necrosis. Also there is a direct relationship between relative expression of Ezrin and Radixin expression. Conclusions: These data support the role of Ezrin and Radixin in the biology of breast cancer and additional studies needed that determine the Ezrin and Radixin associated with phenotype and may validate them as markers of cancer progression and as a potential target for cancer therapy.
1. Azizi Tabesh G, Izadi P, Fereidooni F, Emami Razavi AN, Tavakkoly Bazzaz J. The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients. Cancer Investigation. 2017;35(1):36-42.
2. Mohammadpour H, Hashemi M, Saffari M, Razavi ANE. Comparative Analyses of Villin and HER-2 Genes Expression in Breast Cancer. Archives of Breast Cancer. 2015;2(4):120-4.
3. Moosavi SA, Abdirad A, Omranipour R, Hadji M, Razavi AE, Najafi M. Clinicopathologic features predicting involvement of non-sentinel axillary lymph nodes in Iranian women with breast cancer. Asian Pac J Cancer Prev. 2014;15(17):7049-54.
4. Nankali M, Karimi J, Goodarzi MT, Saidijam M, Khodadadi I, Razavi ANE, et al. Increased Expression of the Receptor for Advanced Glycation End-Products (RAGE) Is Associated with Advanced Breast Cancer Stage. Oncology Research and Treatment. 2016;39(10):622-8.
5. Omranipour R, Karbakhsh M, Behforouz A, Neishaboury M, Mahmoodzadeh H, Koma KB, et al. Performance of the Gail model for breast cancer risk assessment in Iranian Women. Archives of Breast Cancer. 2015;2(1):27-31.
6. Van Deurzen C, Van Hillegersberg R, Hobbelink M, Seldenrijk C, Koelemij R, Van Diest P. Predictive value of tumor load in breast cancer sentinel lymph nodes for second echelon lymph node metastases. Analytical Cellular Pathology. 2007;29(6):497-505.
7. Hall A. The cytoskeleton and cancer. Cancer and Metastasis Reviews. 2009;28(1-2):5-14.
8. Solinet S, Mahmud K, Stewman SF, El Kadhi KB, Decelle B, Talje L, et al. The actin-binding ERM protein Moesin binds to and stabilizes microtubules at the cell cortex. J Cell Biol. 2013:jcb. 201304052.
9. Pei W, Du F, Zhang Y, He T, Ren H. Control of the actin cytoskeleton in root hair development. Plant science. 2012;187:10-8.
10. Al-Maghrabi J, Gomaa W, Buhmeida A, Al-Qahtani M, Al-Ahwal M. Loss of Villin Immunoexpression in Colorectal Carcinoma Is Associated with Poor Differentiation and Survival. ISRN gastroenterology. 2013;2013.
11. Planas-Silva M, Stone M. Selective expression of villin associated with active c-Src tyrosine kinase in tamoxifen-resistant breast cancer cells. Clinical Cancer Research. 2007;13(19 Supplement):B50-B.
12. Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical & experimental metastasis. 2007;24(2):69-78.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods. 2001;25(4):402-8.
14. Neisch AL, Speck O, Stronach B, Fehon RG. Rho1 regulates apoptosis via activation of the JNK signaling pathway at the plasma membrane. The Journal of cell biology. 2010;189(2):311-23.
15. Valdman A, Fang X, Pang S-T, Nilsson B, Ekman P, Egevad L. Ezrin expression in prostate cancer and benign prostatic tissue. European urology. 2005;48(5):852-7.
16. Weng W-H, Åhlén J, Åström K, Lui W-O, Larsson C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clinical Cancer Research. 2005;11(17):6198-204.
17. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nature medicine. 2004;10(2):182-6.
18. Sato N, Funayama N, Nagafuchi A, Yonemura S, Tsukita S. A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. Journal of cell science. 1992;103(1):131-43.
19. Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, et al. Molecular profiling of tumor progression in head and neck cancer. Archives of Otolaryngology–Head & Neck Surgery. 2005;131(1):10-8.
20. Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. International journal of cancer. 2009;124(7):1614-21.
21. Sarrió D, Rodríguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast cancer research and treatment. 2006;98(1):71-9.
22. Takeuchi K, Sato N, Kasahara H, Funayama N, Nagafuchi A, Yonemura S, et al. Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. The Journal of Cell Biology. 1994;125(6):1371-84.
23. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast cancer research. 2005;7(3):R365.
2. Mohammadpour H, Hashemi M, Saffari M, Razavi ANE. Comparative Analyses of Villin and HER-2 Genes Expression in Breast Cancer. Archives of Breast Cancer. 2015;2(4):120-4.
3. Moosavi SA, Abdirad A, Omranipour R, Hadji M, Razavi AE, Najafi M. Clinicopathologic features predicting involvement of non-sentinel axillary lymph nodes in Iranian women with breast cancer. Asian Pac J Cancer Prev. 2014;15(17):7049-54.
4. Nankali M, Karimi J, Goodarzi MT, Saidijam M, Khodadadi I, Razavi ANE, et al. Increased Expression of the Receptor for Advanced Glycation End-Products (RAGE) Is Associated with Advanced Breast Cancer Stage. Oncology Research and Treatment. 2016;39(10):622-8.
5. Omranipour R, Karbakhsh M, Behforouz A, Neishaboury M, Mahmoodzadeh H, Koma KB, et al. Performance of the Gail model for breast cancer risk assessment in Iranian Women. Archives of Breast Cancer. 2015;2(1):27-31.
6. Van Deurzen C, Van Hillegersberg R, Hobbelink M, Seldenrijk C, Koelemij R, Van Diest P. Predictive value of tumor load in breast cancer sentinel lymph nodes for second echelon lymph node metastases. Analytical Cellular Pathology. 2007;29(6):497-505.
7. Hall A. The cytoskeleton and cancer. Cancer and Metastasis Reviews. 2009;28(1-2):5-14.
8. Solinet S, Mahmud K, Stewman SF, El Kadhi KB, Decelle B, Talje L, et al. The actin-binding ERM protein Moesin binds to and stabilizes microtubules at the cell cortex. J Cell Biol. 2013:jcb. 201304052.
9. Pei W, Du F, Zhang Y, He T, Ren H. Control of the actin cytoskeleton in root hair development. Plant science. 2012;187:10-8.
10. Al-Maghrabi J, Gomaa W, Buhmeida A, Al-Qahtani M, Al-Ahwal M. Loss of Villin Immunoexpression in Colorectal Carcinoma Is Associated with Poor Differentiation and Survival. ISRN gastroenterology. 2013;2013.
11. Planas-Silva M, Stone M. Selective expression of villin associated with active c-Src tyrosine kinase in tamoxifen-resistant breast cancer cells. Clinical Cancer Research. 2007;13(19 Supplement):B50-B.
12. Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical & experimental metastasis. 2007;24(2):69-78.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods. 2001;25(4):402-8.
14. Neisch AL, Speck O, Stronach B, Fehon RG. Rho1 regulates apoptosis via activation of the JNK signaling pathway at the plasma membrane. The Journal of cell biology. 2010;189(2):311-23.
15. Valdman A, Fang X, Pang S-T, Nilsson B, Ekman P, Egevad L. Ezrin expression in prostate cancer and benign prostatic tissue. European urology. 2005;48(5):852-7.
16. Weng W-H, Åhlén J, Åström K, Lui W-O, Larsson C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clinical Cancer Research. 2005;11(17):6198-204.
17. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nature medicine. 2004;10(2):182-6.
18. Sato N, Funayama N, Nagafuchi A, Yonemura S, Tsukita S. A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. Journal of cell science. 1992;103(1):131-43.
19. Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, et al. Molecular profiling of tumor progression in head and neck cancer. Archives of Otolaryngology–Head & Neck Surgery. 2005;131(1):10-8.
20. Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. International journal of cancer. 2009;124(7):1614-21.
21. Sarrió D, Rodríguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast cancer research and treatment. 2006;98(1):71-9.
22. Takeuchi K, Sato N, Kasahara H, Funayama N, Nagafuchi A, Yonemura S, et al. Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. The Journal of Cell Biology. 1994;125(6):1371-84.
23. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast cancer research. 2005;7(3):R365.
| Files | ||
| Issue | Vol 14 No 4 (2022) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/bccr.v14i4.14672 | |
| Keywords | ||
| Ezrin Radixin Breast cancer Grade | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Mohammadpour H, Shirkoohi R. Up Regulation of Ezrin and Radixin with respect to Grade of Tumors in Breast Cancer Patients. Basic Clin Cancer Res. 2023;14(4):213-219.
